Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01977768Phase 3Completed

TB Immunotherapy Trial With Heat-killed M. Vaccae

Role: collaborator

NCT01061593Phase 3Completed

Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV

Role: lead

NCT01380119Phase 2Completed

Tuberculosis (TB) Immunotherapy Phase 2 Study

Role: lead

NCT01222338Phase 2Completed

Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients

Role: lead

All 4 trials loaded